Should I Buy Resmed Shares in Australia in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Resmed for over three years. Every month, hundreds of thousands of users in Australia trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Resmed.

What is Resmed?

How much is Resmed stock?

The price of Resmed stock is rising this week. Currently trading at $256.26 USD, Resmed has fluctuated between $254.88 and $258.04 in the last 24 hours and is up solidly this week, maintaining a market capitalisation of $37.6 billion USD. The average three-month trading volume is 1.04 million shares, with a price/earnings ratio around 28.7, a dividend yield of roughly 0.83%, and a beta of 0.77, indicating lower volatility versus the broader market. Resmed’s mix of robust market leadership and ongoing innovation supports its appeal as a quality healthcare stock.

Our full analysis of the Resmed stock

After a thorough review of Resmed's most recent financial results and a close analysis of the stock’s performance over the past three years, we have synthesised key financial indicators, technical signals, market developments, and industry peer comparisons using our proprietary analytical models. This holistic approach brings new clarity to Resmed’s investment case from both a qualitative and quantitative perspective. So, why might Resmed stock once again become a strategic entry point into the global healthcare technology sector in 2025?

Recent performance and market context

Resmed has shown renewed strength in 2025, reflecting the recovery and long-term growth of the medical technology sector. The share price currently stands at about $256.26 USD, trading near the upper end of its 52-week range ($187.50 – $263.05). Over the past week, the stock has displayed resilience and has continued to approach multi-year highs, buoyed by robust quarterly results and market optimism. Notably, Resmed's Q3 2025 results topped analyst expectations—revenue grew by 8% year-on-year, and earnings per share surged 22%. The successful launch of NightOwl™, a groundbreaking at-home sleep test, as well as a meta-analysis in *The Lancet Respiratory Medicine* confirming CPAP therapy efficacy, have been well received by the market. These advances come as ageing demographics and the global focus on respiratory health create a favourable macro environment for Resmed's solutions. Despite past volatility linked to concerns over GLP-1 obesity drugs, consensus sentiment has shifted decisively positive as Resmed has demonstrated ongoing demand and margin expansion.

Technical analysis

Resmed’s technical set-up underscores persistent accumulation and potential for further upside. At present, all principal moving averages (MA20 at $253.58, MA50 at $247.17, MA100 at $235.51, and MA200 at $238.32) provide clear technical support, with the stock trading firmly above each, indicating a strong upward trend. The RSI of 61.87 points to bullish yet stable momentum, avoiding short-term overbought signals and showing healthy rotation. While the current MACD value of 3.17 offers a cautionary note for immediate pullbacks, the majority of technical indicators (14 out of 15 moving averages) remain bullish. Key support lies at $245.21, with resistance at $265.51—should strong volume continue, a break above resistance could signify a new breakout phase. The recent clustered consolidation just below highs further sets the stage for a potential decisive move upward, supported by institutional accumulation and strong investor confidence.

Fundamental analysis

Resmed’s fundamentals are among the strongest in the global medtech universe, underpinned by consistent double-digit annual growth, robust profitability, and outstanding innovation credentials. Q3 2025 revenue reached $1.29 billion (USD), up 8% year-on-year (9% at constant currency), while operating profit grew 14% and gross margin expanded to an exceptional 59.3%. The company’s P/E ratio stands between 28.6–28.9, a reflection of the premium awarded to high-quality healthcare growth but still reasonable when benchmarked against its sustained revenue expansion, sector-leading profitability, and cash generation. Resmed’s dividend yield of about 0.83% is modest, but notable for its 13 years of uninterrupted increases— a testament to the company’s financial discipline and shareholder focus.

Strategic expansion continues apace, as Resmed further cements its reputation as the “gold standard” for sleep apnoea solutions. The multi-layered business model—integrating connected therapeutic devices, cloud-based platforms, and residential care software—generates both recurring device sales and high-margin software revenue (the latter up 10% this year). Investment in R&D remains strong at 6.5% of sales, with management demonstrating a clear long-term commitment to technological leadership and new product pipelines. Brand strength, regulatory leadership, and deep relationships with healthcare professionals serve as enduring competitive moats. Importantly, market exposure now covers more than 140 countries, minimising reliance on any single healthcare system.

Volume and liquidity

Liquidity in Resmed stock remains exemplary, with average three-month daily turnover at 1.04 million shares and a total market capitalisation of $37.6 billion USD. This ensures excellent price discovery and flexibility for both institutional and Australian retail investors. The float is substantial, also bolstered by the company’s dual listing (NYSE and ASX CDIs), promoting transparency and facilitating dynamic valuation adjustments in response to news flow or market developments. This depth and liquidity reduce volatility and provide a solid foundation for market confidence during periods of sector uncertainty or broad rotation.

Catalysts and positive outlook

• Product innovation: The FDA-cleared NightOwl™ device redefines at-home sleep testing, expanding Resmed’s TAM and supporting future growth.
• Clinical leadership: Published RCTs and meta-analyses affirming CPAP therapy’s benefits substantiate Resmed’s core value proposition and drive physician adoption.
• Brand evolution: Unification of product portfolios increases cross-selling opportunities, strengthens identity, and streamlines go-to-market execution.
• Pipeline and R&D: Ongoing investment produces a rich portfolio of digital health innovations and next-gen devices, ensuring resilience against competition.
• ESG and sustainability: Resmed’s leadership in respiratory care dovetails with global public health trends, while new carbon reporting and social initiatives enhance appeal for responsible investors.
• Market expansion: The addressable market of 2.3 billion individuals with sleep/respiratory disorders represents enormous untapped demand, particularly as diagnoses rise in emerging markets.
• Strategic acquisitions: M&A activity could further supplement growth and unlock new revenue verticals in adjacent care segments.
• Analyst upgrades: The consensus “Moderate Buy” is reinforced by upward price target revisions (mean target $259.33, with room to $295 and beyond).

All told, Resmed’s expanding ecosystem of products, services, and data-driven insight, alongside demographic and regulatory tailwinds, creates a well-defined and sustainable path to multi-year value creation.

Investment strategies

For short-term traders, Resmed’s current chart pattern and positive momentum within a broad trading channel lend themselves well to tactical entries. The recent bullish trend, along with clear horizontal support near $245 and a technical target toward $265/$295, offers the possibility of attractive risk/reward trades. Short stints of consolidation or minor pullbacks can serve as ideal timing windows before a break higher, enabling nimble market participants to capture upside.

Medium-term investors benefit from visibility on both earnings trajectory and product pipeline. With quarterly revenue growth, margin improvement, and sequential dividend hikes, Resmed stands out against both local and global healthcare alternatives. The robust balance sheet, wide geographic diversification, and annuity-like revenue stream from recurring devices and digital ecosystem subscriptions further reinforce the investment case.

For long-term holders, Resmed represents a core allocation in a portfolio favouring healthcare innovation and secular growth. The company’s durable market leadership, compounded by global demographic trends (ageing populations, chronic disease management), near-insatiable demand for cost-effective care, and unyielding commitment to R&D, signal enduring compounding returns. Accumulating the stock ahead of major product launches or earnings reports, and during periods of sector rotation, aligns well with long-term value creation.

Optimal positioning remains to accumulate on dips near technical support levels or prior to anticipated clinical or innovation milestones, as well as in advance of regulatory tailwinds enhancing sector valuations.

Is it the right time to buy Resmed?

On all critical measures, Resmed emerges as a compelling growth and quality story, with a proven track record of innovation, expanding profitability, and global scale. The fundamentals justify renewed interest: leadership in a rapidly expanding addressable market, impressive and durable margins, accelerating product pipeline, and tangible brand strength all support the case for fresh capital deployment. The stock’s valuation, while reflective of strong growth expectations, remains reasonable within the context of sector peers and Resmed’s differentiated positioning. Supported by ongoing product innovation, adoption by clinicians, and increasing rates of diagnosis, the company’s growth trajectory appears set to continue at above-industry rates.

Resmed seems to represent an excellent opportunity for Australian investors seeking reliable exposure to world-leading healthcare technology and long-term secular growth. With powerful fundamentals, strong technical backing, and visible future catalysts, it appears poised to enter a new bullish phase—a compelling candidate for serious consideration in growth-focused and diversified portfolios.

How to buy Resmed stock in Australia?

Buying Resmed stock online is straightforward and secure with an Australian-regulated broker. You can choose between two main methods: purchasing shares directly for long-term ownership (spot buying) or trading Contracts for Difference (CFDs) for leveraged opportunities. Both approaches offer flexibility for new and experienced investors. To ensure you get the best fit for your needs, you’ll find a detailed broker comparison further down this page.

Spot buying

A cash purchase of Resmed stock means you buy and own the shares in your brokerage account. Typical fees include a fixed commission per order, often around AUD $5–$10 with most local brokers.

Example of share purchase calculation

If the Resmed share price is $256.26 AUD, you can buy around 3 shares with a $1,000 AUD stake, including a brokerage fee of around $5.

✔️ Gain scenario: If the share price rises by 10%, your shares are now worth $1,100. Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading on Resmed shares lets you speculate on price movements without owning the shares. With CFDs, you pay a spread (the broker’s price difference) and a small overnight financing fee when holding a position open.

Gain scenario

You open a CFD position on Resmed shares, with 5x leverage. This gives you a market exposure of $5,000 AUD.

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 AUD (excluding fees).

Final advice

Always compare brokers’ fees, available platforms, and trading conditions before investing in Resmed shares. Your choice between spot buying and CFDs should be guided by your financial goals and risk appetite. For more help, a broker comparison is available further down the page.

Our 7 tips for buying Resmed stock

The latest news about Resmed

Resmed stock reached new 52-week highs, supported by technical strength and consistent positive market sentiment. Shares traded up to USD 263.05, with strong buying above all key moving averages. Technical indicators, including a positive summary technical signal, have highlighted momentum, and the stock remains well supported at AUD 245 on ASX (CDI form). This ongoing strength reflects both local and global investor confidence.

Resmed reported record quarterly results with robust revenue and earnings growth, exceeding analyst expectations. Q3 2025 delivered revenue growth of 8% year-on-year and a 22% increase in earnings per share, well ahead of consensus. Operating margins continued to improve, highlighting operational leverage and strategic execution. Australian institutional investors have responded positively to this improvement in fundamentals.

The launch and FDA approval of NightOwl™ home sleep apnea test provide new opportunities in the home diagnostics market. This innovation, now available in Australia, positions Resmed advantageously in non-hospital sleep health. Local distributors and healthcare partners have praised the product’s accessibility and the expansion of the digital health portfolio, reinforcing Resmed’s market leadership in Australia and beyond.

Resmed maintained a stable dividend payout and ongoing share price recovery through enhanced investor confidence. The latest quarterly dividend stands at USD 0.53 per share, with thirteen consecutive years of dividend growth. The reliable dividend policy, coupled with sustained cash generation, has continued to appeal to local Australian income-focused investors, especially SMSF trustees seeking global healthcare exposure.

GLP-1 obesity drug concerns have dissipated, bolstering analyst outlook and sector demand for Resmed’s solutions. Market fears about the impact of weight loss medications on sleep apnea device demand have receded, reflected in strong analyst “Buy” consensus and robust order books. This sentiment shift has contributed to a more optimistic environment for Resmed stock across the Australian and global healthcare markets.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.